Carbapenemase-Producing Organism and Vancomycin-Resistant Enterococcus Management

Plain-language summary

This study examines the use of molecular assays to screen for multidrug-resistant bacteria (carbapenemase-producing organisms and vancomycin-resistant enterococcus). It enrolled people who met at least one risk criterion for screening, such as a history of hospitalization or being a carrier of resistant bacteria. It was conducted as a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University Hospital, Grenoble

Intervention

molecular assays to screen for eXDR

Start date

2/18/2022

Estimated completion

3/31/2023

Countries

France

Related genes

Locations

• Grenoble, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Anybody coming in the CHUGA with at least one criteria of eXDR screening:

* Hospitalized patients at least two times within the previous year
* Patient transferred from another hospital
* Patient transferred from nursing home
* Patient with a history of hospitalization abroad (foreign countries) within the previous year
* Contact patient = patient exposed to an eXDR bacteria carrier
* eXDR carrier

Exclusion Criteria:

* Refusal to participate to the study. Opposition of the patients to the use of their personal data.
* Refusal of rectal swab